Oculis raises at-the-market share sale capacity to $125 million

Oculis Holding AG entered into Amendment No. 1 to its Amended and Restated Sales Agreement with Leerink Partners LLC on November 3, 2026, increasing the maximum aggregate offering price of ordinary shares it may offer and sell under the agreement from $100,000,000 to an amount that would not exceed what is registered on an effective registration statement for which a prospectus or prospectus supplement has been filed before the offering begins.¹ After the amendment, Oculis has capacity to offer and sell up to an aggregate $125,000,000 of ordinary shares under the Amended Sales Agreement.¹

The original agreement, dated March 4, 2026, covered the offer and sale of up to $100,000,000 of ordinary shares through Leerink Partners acting as sales agent or principal.¹ As of the date of the new prospectus supplement, Oculis had sold $61,323,500 of ordinary shares under that agreement.¹

Oculis ordinary shares trade on The Nasdaq Global Market and The Nasdaq Iceland Main Market under the symbol "OCS."¹ On November 2, 2026, the shares last traded at $7.71 on Nasdaq and at ISK 994.00 on Nasdaq Iceland.¹

Under the arrangement, Leerink Partners' compensation will be up to 3.0% of gross proceeds from any shares sold under the agreement.¹ Oculis also agreed to reimburse Leerink Partners for certain legal and FINRA counsel fees, capped at $55,000, plus up to $25,000 per calendar quarter for ongoing diligence-related legal costs.¹ The company estimated total offering expenses, excluding compensation to Leerink Partners, at approximately $1,500,000.¹

Because there is no minimum offering amount required to close the offering, the actual total amount sold, commissions, and net proceeds are not yet determinable.¹